Home » Archive by Category

Syndication

Field Service Engineer (Greater San Diego Area)

December 17, 2014 – 9:46 am | Edit Post

Field Service Engineer
For 25 years our company services biotechnology and pharmaceutical industries, focusing on repair, calibration and validation of laboratory equipment.
Our work environment encourages curiosity and creativity, nurtures teamwor [...]

QC Associate II

December 17, 2014 – 9:13 am | Edit Post

BioPhase Solutions specializes in recruiting top talented professionals for San Diego’s Scientific community. We are currently looking for a QC Associate II to work for a leading San Diego biotechnology company.
QC Associate II
Responsible for ensu [...]

Halozyme allies with Janssen Biotech

December 17, 2014 – 8:56 am | Edit Post

Halozyme advances reach of drug delivery technology.

Su Lab: BioGPS Featured Article – siRNA screen for genes that affect Junin virus entry uncovers voltage-gated calcium channels as a therapeutic target

December 17, 2014 – 8:00 am | Edit Post

BioGPS has become the valuable resource that it is because of the contributions from our wonderful user community. Thank you […]

Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE™ Technology

December 17, 2014 – 7:00 am | Edit Post

SAN DIEGO, Dec. 17, 2014 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Janssen Biotech, Inc. (Janssen) for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme’s ENHANZE™ technology. ENHANZE is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies hyaluronan, a component of the extracellular matrix, to aid in the dispersion and absorption of other injected therapeutic drugs.

“We are pleased that Janssen, a global leader in the development of novel therapeutics, has selected our ENHANZE technology to further augment their development pipeline,” said Dr. Helen Torley, President and Chief Executive Officer. “This new global licensing agreement further validates our ENHANZE platform technology, which we believe may benefit a growing number of patients worldwide by making therapies more convenient.”

Under the terms of the agreement, Halozyme has granted to Janssen a worldwide license to develop and commercialize products for up to five targets combining rHuPH20 with Janssen’s proprietary compounds.  Halozyme will receive an initial payment of $15 million, and is eligible to receive additional payments upon Janssen’s achievement of specified development, regulatory and sales-based milestones, totaling up to $566 million. Halozyme is also entitled to royalty payments based on net sales of products using the ENHANZE technology. Under the collaboration, Janssen will also obtain access to Halozyme’s expertise in developing and applying rHuPH20 to Janssen targets and will obtain a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and Janssen target compounds resulting from the collaboration.

About ENHANZE™

ENHANZE™ is Halozyme’s proprietary drug delivery platform based on the Company’s patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously (just under the skin). By using rHuPH20, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously. ENHANZE may also benefit subcutaneous biologics by reducing the need for multiple injections. This delivery has been shown in studies to reduce health care practitioner time required for administration and shorten time for drug administration.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company’s research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme’s pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer and Baxter. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the development and commercialization of product candidates under the Halozyme-Janssen collaboration, the potential benefits and attributes of such product candidates, the possible receipt by Halozyme of future payments including milestones and royalties) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events, competitive conditions and the continuation of the Halozyme-Janssen collaboration. These and other factors that may result in differences are discussed in greater detail in Halozyme’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2014.

Investor Contact:Schond GreenwayHalozyme Therapeutics858-704-8352ir@halozyme.com

Media Contact:Susan Neath Francis212-301-7182sfrancis@w2ogroup.com

Logo - http://photos.prnewswire.com/prnh/20100302/LA63139LOGO

 

SOURCE Halozyme Therapeutics, Inc.

Senior Facilities Project Engineer – Oceanside Biologics – Gilead – Oceanside, CA

December 17, 2014 – 6:47 am | Edit Post

 Provides project leadership by developing scope alternatives and project contracting / procurement strategies Sets up logistics system, including RFQs, bid…
From Gilead – 17 Dec 2014 13:47:53 GMT
– View all Oceanside jobs

Sr. Chemist with Polymer Experience-Revlon (La Jolla)

December 17, 2014 – 6:24 am | Edit Post

Purpose Statement:
This position is responsible for the conception and managing of all phases of research and product development until first production completed. The Sr. R&D Research Chemist will uphold the highest standards while maintaining the [...]

Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus

December 17, 2014 – 6:00 am | Edit Post

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2014 /PRNewswire/ — Tigercat Pharma, Inc. today announced positive results of a Phase 2 study evaluating the investigational oral NK-1 receptor antagonist VPD-737 (serlopitant), for the treatment of patients with severe, chronic itch who are unresponsive or inadequately responsive to the current standard of care, including topical steroids and antihistamines.

The primary efficacy endpoint was percent change in Visual Analog Scale (VAS) itch score from baseline, comparing drug to placebo for each dose group. Statistically significant reduction in VAS scores were seen in both the 1mg and 5mg dose groups. The response was durable over the entire treatment period.  VPD-737 is safe and well tolerated.

Gil Yosipovitch, M.D, Professor Chair of Dermatology and Director of the Temple Itch Center at Temple University School of Medicine, a principal investigator for the Phase 2 study remarked: “Today is an important day for patients who suffer from severe, chronic pruritus.   The results of this study give tremendous hope for the millions of patients who suffer from this debilitating condition, which erodes their quality of life.  I look forward to the further development of VPD-737 and hopefully adding it to the treatment armamentarium for patients suffering from intractable pruritus.”

Edward Schnipper, M.D., a Founder and Chief Medical Officer at Tigercat Pharma, Inc. remarked: “We are very pleased with the conduct and outcome of this study. We are continuing development of this drug for patients who desperately need a treatment regimen more efficacious than the current standard of care.”

About the Phase 2 StudyThe Phase 2 study was a randomized, double-blind, parallel group, placebo-controlled, dose-finding and efficacy study of VPD-737 (serlopitant) for the treatment of patients with chronic pruritus.    

The study enrolled 257 patients from 25 sites in the United States with VAS of 7 or greater at baseline (on a scale of 1 to 10). Patients were males and females between 18 and 65 years with confirmed chronic pruritus for a period lasting more than six weeks. Patients were unresponsive or inadequately responsive to topical steroids or antihistamines.

The patients were randomized into four equal groups of the following doses: 0.25, 1, 5 mg and placebo tablets administered daily for 6 weeks. The primary efficacy endpoint was the percent change in VAS from baseline, comparing drug to placebo for each dose group. The primary analysis was conducted on an Intent-to-Treat (ITT) population.

Tigercat utilized the services of TKL Research, Inc., a contract research organization, to conduct the trial.

ABOUT TIGERCAT PHARMA, INC.Tigercat Pharma, Inc., is a clinical stage biopharmaceutical company focused on the development and commercialization of VPD 737(serlopitant), an NK-1 receptor antagonist, currently in late stage clinical development for the treatment of chronic pruritus. Tigercat investors included Velocity Pharmaceutical Holdings, LLC, and Remeditex Ventures, LLC.  More information is available at www.tigercatpharma.com.

ABOUT VELOCITY PHARMACEUTICAL DEVELOPMENT, LLC Velocity Pharmaceutical Development (VPD) is a pharmaceutical development organization dedicated to rapidly advancing promising drug candidates to clinical proof of concept using a highly virtual management model. VPD seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. VPD then manages a development program for each drug candidate intended to generate convincing human proof of concept data (generally by conducting a phase 2 clinical trial). Following successful human proof of concept, VPD then seeks a large pharmaceutical company acquirer for each program. VPD is staffed by a seasoned team of clinical drug developers with expertise identifying attractive drug candidates, target markets, and designing and managing outsourced clinical trials. This expert team manages multiple single asset companies to remove the costly overhead and misaligned incentives present in traditional biotechnology company structures. VPD believes this new capital-efficient model will yield attractive new drugs to treat patients with significant unmet clinical needs. The company is located in South San Francisco, California. More information is available at www.vpd.net.

ABOUT VELOCITY PHARMACEUTICAL HOLDINGS, LLC Velocity Pharmaceutical Holdings, LLC, is an entity funded by CMEA Capital that makes investments in highly virtual, project-focused pharmaceutical development companies that are managed by Velocity Pharmaceutical Development, LLC. More information is available at www.vpd.net and www.cmea.com.

ABOUT REMEDITEX VENTURES, LLC Remeditex seeks to develop opportunities in need of commercial validation, guidance, and capital. Its mission is to develop early stage biomedical science and make Texas and Colorado a preferred location for biotechnology companies, venture capitalists, and entrepreneurs by accelerating the pace of commercialization of biomedical research; help create and support a thriving biotechnology industry; attract biotech venture capital to Texas and Colorado; and achieve significant returns to support the next generation of promising science. More information is available at www.remeditex.com.

General inquires:

Leslie LovenVelocity Pharmaceutical Development1-415-524-7326 leslie@vpd.net

Media inquiries:

Hunter MarshallMacDougall Biomedical CommunicationsMain: 1-650-339-7533Direct: 1-510-693-2792 hmarshall@macbiocom.com 

 

SOURCE Velocity Pharmaceutical Development

Synageva BioPharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 at 9:00 a.m. PST

December 17, 2014 – 6:00 am | Edit Post

LEXINGTON, Mass., Dec. 17, 2014 /PRNewswire/ – Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today its presentation at the upcoming J.P. Morgan Healthcare Conference being held in San Francisco, CA.

Sanj K. Patel, President and Chief Executive Officer, will present on Monday, January 12, 2015, at 9:00 a.m. PST (12:00 p.m. EST).  The presentation will be webcast live and may be accessed from the “Webcasts & Presentations” section of the “Investor Relations” tab on the home page of Synageva’s website at www.synageva.com.

Synageva routinely posts information that may be important to investors in the “Investor Relations” section of the company’s website at www.synageva.com.  Synageva encourages investors and potential investors to consult this website regularly for important information about the company.

Further information regarding Synageva is available at www.synageva.com.

“Synageva BioPharma” is a trademark, and “Dedicated to Rare Diseases” is a registered trademark, of Synageva. 

SOURCE Synageva BioPharma Corp.

Synageva BioPharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 at 9:00 a.m. PST

December 17, 2014 – 6:00 am | Edit Post

LEXINGTON, Mass., Dec. 17, 2014 /PRNewswire/ – Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today its presentation at the upcoming J.P. Morgan Healthcare Conference being held in San Francisco, CA.

Sanj K. Patel, President and Chief Executive Officer, will present on Monday, January 12, 2015, at 9:00 a.m. PST (12:00 p.m. EST).  The presentation will be webcast live and may be accessed from the “Webcasts & Presentations” section of the “Investor Relations” tab on the home page of Synageva’s website at www.synageva.com.

Synageva routinely posts information that may be important to investors in the “Investor Relations” section of the company’s website at www.synageva.com.  Synageva encourages investors and potential investors to consult this website regularly for important information about the company.

Further information regarding Synageva is available at www.synageva.com.

“Synageva BioPharma” is a trademark, and “Dedicated to Rare Diseases” is a registered trademark, of Synageva. 

SOURCE Synageva BioPharma Corp.